Moreover, it was shown that andrographolide inhibits VICs calcification via the NF-kappa B/Akt/ERK pathway in vitro, which supports our data regarding ERK1/2 to be a promising target for selective therapy against aortic valve calcification [53]. The gene discussed is AKT1; the disease is aortic valve calcification.